(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

# (19) World Intellectual Property Organization International Bureau



# 

### (43) International Publication Date 4 January 2001 (04.01.2001)

### **PCT**

# (10) International Publication Number WO 01/01218 A3

(51) International Patent Classification7: 17/00, G01N 33/48, 33/50, G06T 1/00

G06F 7/00,

(21) International Application Number: PCT/US00/17540

(22) International Filing Date: 26 June 2000 (26.06.2000)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/141,521

25 June 1999 (25.06.1999) U

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:

US Filed on 60/141,521 (CIP) 25 June 1999 (25.06.1999)

(71) Applicant (for all designated States except US): GENAIS-SANCE PHARMACEUTICALS, INC. [US/US]; Five Science Park, New Haven, CT 06511 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): DENTON, Richard, Rex [US/US]; 129 Hunters Trail, Madison, CT 06443 (US). JUDSON, Richard, S. [US/US]; 42 Baker Hill Drive, Guilford, CT 06437 (US). RUAÑO, Gualberto [US/US]; 88 Lawrence Street, New Haven, CT 06511 (US). STEPHENS, Joel, Claiborne [US/US]; 46 Crabapple Lane, Guilford, CT 06437 (US). WINDEMUTH, Andreas, K. [DE/US]; 91 Center Road, Woodbridge, CT 06524 (US). XU, Chuanbo [CN/US]; 524 Openint Hill Road, Madison, CT 06443 (US).

- (74) Agents: MOROZ, Eugene et al.; Morgan & Finnegan, L.L.P., 345 Park Avenue, New York, NY 10154 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR. HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ. UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

#### Published:

- With international search report.
- (88) Date of publication of the international search rep rt: 7 June 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS FOR OBTAINING AND USING HAPLOTYPE DATA

(57) Abstract: Methods, computer program(s) and database(s) to analyze and make use of gene haplotype information. These include methods, program, and database to find and measure the frequency of hapl types in the general population; methods, program, and database to find correlation's between an individual's haplotypes r genotypes and a clinical outcome; methods, program, and database to predict an individual's haplotypes from the individual's genotype for a gene; and methods, program, and database to predict an individual's clinical response to a treatment based on the individual's genotype or haplotype.

		• • • • • • • • • • • • • • • • • • • •
•		
		<del>-</del>
	·	

-

#### INTERNATIONAL SEARCH REPORT

International application No. PCT/US00/17540

#### **B. FIELDS SEARCHED**

Electronic data bases consulted (Name of data base and where practicable terms used):

DIALOG (files 5, 155) and EAST (files U.S. Patents, European abstracts, Japanese abstracts, and Derwent) search terms: pharmacogenomic, pharmacogenetic, haplotype, genotype, database, computer, clinical trial, population genetics, polymorphism, SNP, Hardy-Weinberg, Mendelian, linkage, phylogenetic, pedigree, locus, gene, phased, unphased

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 15.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s)1-8, 69-72, and 120-124, drawn to a method of generating a haplotype database, computer-usable medium, and computer programmed therefore.

Group II, claim(s) 8-12 and 75, drawn to a method of predicting the presence of a haplotype and computer-usable medium therefore.

Group III, claim(s) 18-21, 74-78, and 125-129, drawn to a method of identifying correlation between haplotype pair and clinical response, computer-usable medium, and computer programmed therefore.

Group IV, claim(s) 22-29, 79-82, 150-155, drawn to a method for determining susceptibility to a condition/disease, computer-usable medium, and computer programmed therefore.

Group V, claim(s) 30-33, 83-84, and 134-135, drawn to a method for predicting response to treatment, computer-usable medium, and computer programmed therefore.

Group VI, claim(s) 34, 85, and 186, drawn to a method for generating a tree structure, computer-usable medium, and computer programmed therefore.

Group VII, claim(s) 35, 86, and 137, drawn to a method for displaying haplotype pair frequency, computer-usable medium, and computer programmed therefore.

Group VIII, claim(s) 56-57, 87-88, and 158-159, drawn to a method for displaying a linkage screen, computer-usable medium, and computer programmed therefore.

Group IX, claim(s) 58-40, 89-61, and 140-142, drawn to a method for displaying a phylogenetic tree screen, computerusable medium, and computer programmed therefore.

Group X, claim(s) 41-42, 92-93, and 143-144, drawn to a method for displaying genotypic analysis, computer-usable medium, and computer programmed therefore.

Group XI, claim(s) 45-51, 94-102, and 145-153, drawn to a method to displaying clinical response values, computerusable medium, and computer programmed therefore.

Group XII, claim(s) 52, 103, and 154, drawn to a method for carrying out a genetic algorithm, computer-usable medium, and computer programmed therefore.

Group XIII, claim(s) 55, 104, and 155, drawn to a method for displaying correlations, computer-usable medium, and computer programmed therefore.

Group XIV, claim(s) 54-55, 105-106, and 156-157, drawn to a method for conducting a clinical trial, computer-usable medium, and computer programmed therefore.

Group XV, claim(s) 56-58, 107-109, and 158-160, drawn to a method for inferring genotype, computer-usable medium, and computer programmed therefore.

Group XVI, claim(s) 59-68, 110-119, and 161-170, drawn to a method of determining polymorphic sites or subhaplotypes, computer-usable medium, and computer programmed therefore.

Group XVII, claim(s) 171-175 and 185, drawn to a data structure.

Group XVIII, claim(s) 176-182, drawn to a method for storing and organizing biological information.

The inventions listed as Groups I-XVIII do not relate to a single inventive concept under PCT Rule 15.1 because, under PCT Rule 15.2, they lack the same or corresponding special technical features for the following reasons: The special technical feature of each method is the starting materials, method steps, and goal of each method. The corresponding computer-usable medium and computer programmed therefore form part of the inventive concept with each method. Note that PCT Rule 15 does not provide for multiple methods or products.

# INTERNATIONAL SEARCH REPORT

International application No. PCT/US00/17540

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)		
This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:		
1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:		
2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed require such an extent that no meaningful international search can be carried out, specifically:	ements to	
5. Claims Nos.:  because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule	e 6.4(a).	
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)		
This International Searching Authority found multiple inventions in this international application, as follows:		
Please See Extra Sheet.		
	3 g##	
1. As all required additional search fees were timely paid by the applicant, this international search reposearchable claims.	ort covers all	
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not in of any additional fee.	nvite payment	
3. X As only some of the required additional search fees were timely paid by the applicant, this international	search report	
covers only those claims for which fees were paid, specifically claims Nos.: 1-21,30-33,35,43-51,53-58,69-78,83-84,86,94-102,104-109,120-129,134-135,137,145-153,155-160,171-183		
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:		
. The state of the	1	
Remark on Protest  X The additional search fees were accompanied by the applicant's protest.		
No protest accompanied the payment of additional search fees.		

C (Continua	ntion). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	
Y	CLARK et al. Haplotype Structure and Population Genetic Inferences from Nucleotide-Sequence Variation in Human Lipoprotein Lipase. American Journal of Human Genetics. 1998, Vol. 63, pages 595-912, see entire document.	1-21,30-33,35,43-51,53-58,69-78,83-84,86,94-102,104-109,120-129,134-135,137,145-153,155-160,171-183	
Y	CASHMAN et al. The Irish cystic fibrosis database. Journal of Medical Genetics. 1995, Vol. 32, No. 12, pages 972-975, see entire document.	1-21,30-33,35,43- 51,53-58,69-78,83- 84,86,94-102,104- 109,120-129,134- 135,137,145- 153,155-160,171- 183	
Y, P	TISHKOFF et al. The Accuracy of Statistical Methods for Estimation of Haplotype Frequencies: An Example from the CD4 Locus. American Journal of Human Genetics. August 2000, Vol. 67, No. 2, pages 518-522, see entire document.	1-21,30-33,35,43- 51,53-5869-78, 83- 84,86,94-102,104- 109,120-129,134- 135,137,145- 153,155-160,171- 183	
Y	PERLIN et al. Toward Fully Automated Genotyping: Allele Assignment, Pedigree Construction, Phase Determination, and Recombination Detection in Duchenne Muscular Dystrophy. American Journal of Human Genetics. 1994, Vol. 55, No.4, pages 777-787, see entire document.	1-21,30-33,35,43-51,53-58,69-78,83-84,86,94-102,104-109,120-129,134-135,137,145-153,155-160,171-183	
Y	HOANG et al. PAH Mutation Analysis Consortium Database: A Database for Disease-producing and Other Allelic Variation at the Human PAH Locus. Nucleic Acids Research. 1996, Vol. 24, No. 1, pages 127-131, see entire document.	1-21,30-33,35,43-51,53-58,69-78,83-84,86,94-102,104-109,120-129,134-135,137,145-153,155-160, 171-183	
Y, P	STEPHENS et al. Single-nucleotide Polymorphisms, Haplotypes, and Their Relevance to Pharmacogenetics. Molecular Diagnosis. December 1999, Vol. 4, No. 4, pages 309-317, see entire document.	1-21,30-33,35,43-51,53-58,69-78,83-84,86,94-102,104-109,120-129,134-135,137,145-153,155-160, 171-183	

C (Continue	ation). DOCUMENTS CONSIDERED TO BE RELEVANT	
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	KLEYN et al. Genetic Variation as a Guide to Drug Development. Science. 18 September 1998, Vol. 281, pages 1820-1821, see entire document.	1-21,30-33,35,43- 51,53-58,69-78,83- 84,86,94-102,104- 109,120-129,134- 135,137,145- 153,155-160,171- 183
Y	MORI et al. HLA Gene and Haplotype Frequencies in the North American Population. Transplantation. 15 October 1997, Vol. 64, No. 7, pages 1017-1027, see entire document.	1-21,30-33,35,43-51,53-58,69-78,83-84,86,94-102,104-109,120-129,134-135,137,145-153,155-160,171-183
Y	MORI et al. Computer program to predict likelihood of finding an HLA-matched donor. Methodology, validation, and application. Biology of Blood and Marrow Transplantation. October 1996, Vol. 2, pages 134-144, see entire document.	1-21,30-33,35,43- 51,53-58,69-78,83- 84,86,94-102,104- 109,120-129,134- 135,137,145- 153,155-160,171- 183
Y	MATISE, T. C. Genome Scanning for Complex Disease Genes Using the Transmission/Disequilibrium Test and Haplotype-based Haplotype Relative Risk. Genetic Epidemiology. 1995, Vol. 12, No. 6, pages 641-645, see entire document.	121,30-33,35,43- 51,53-58,69-78,83- 84,86,94-102,104- 109,120-129,134- 135,137,145- 153,155-160,171- 183
Y	COOPER et al. Network Analysis of Human Y Microsatellite Haplotypes. Human Molecular Genetics. 1996, Vol. 5, No. 11, pages 1759-1766, see entire document.	1-21,30-33,35,43-51,53-58,69-78,83-84,86,94-102,104-109,120-129,134-135,137,145-153,155-160,171-183
Y	GENE et al. Haplotype frequencies of eight Y-chromosome STR loci in Barcelona (North-East Spain). International Journal of Legal Medicine. 1999, Vol. 112, pages 403-405, see entire document.	1-21,30-33,3543,- 51,53-58,69-78,83- 84,86,94-102,104- 109,120-129,134- 135,137,145- 153,155-160,171- 183

C (Continue	ution). DOCUMENTS CONSIDERED TO BE RELEVANT	
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,773,220 A (DEKOSKY ET AL) 30 June 1998 (30-06-98), see in particular abstract and claims.	1-21,30-33,35,43- 51,53-58,69-78,83- 84,86,94-102,104- 109,120-129,134- 135,137,145-15 3,155-160,171-183
Y,P	US 5,972,614 A (RUANO ET AL) 26 October 1999 (26-10-99), see in particular abstract; claims; column 6, lines 33-55; column 12, lines 10-25.	1-21,30-33,35,43- 51,53-58,69-78,83- 84,86,94-102,104- 109,120-129,134- 135,137,145-15 3,155-160, 171-183
<b>Y, P</b>	US 6,022,683 A (POIRIER) 08 February 2000 (08-02-00), see in particular abstract and claims.	1-21,30-33,35,43- 51,53-58,69-78,83- 84,86,94-102,104- 109,120-129,134- 135,137,145- 153,155-160, 171- 183
Y, P	US 6,043,040 A (ACTON) 28 March 2000 (28-03-00), see in particular abstract, claims, and columns 49-59.	1-21,30-33,35,43- 51,53-58,69-78,83- 84,86,94-102,104- 109,120-129,134- 135, 137,145- 153,155-160,171- 183
Y	US 5,648,482 A (MEYER) 15 July 1997 (15-07-97), see in particular abstract, claims, and columns 23-26.	1-21,30-33,35,43- 51,53-58,69- 78,8384,86,94- 102,104-109,120- 129,134-135,1 37,145-153,155- 160,171-183
Y, P	US 6,030,778 A (ACTON ET AL) 29 February 2000 (29-02-00), see in particular abstract, claims, and columns 25-30.	1-21,30-33, 35,43- 51,53-58,69-78,83- 84,86,94-102,104- 109,120-129,134- 135,137,145- 153,155-160,171-

# INTERNATIONAL SEARCH REPORT

International application No. PCT/US00/17540

			PC17US00/1	18 <del>1</del> 0
A. CLASSIFICATI N F SUBJECT MATTER  IPC(7) :G06F 7/00, 17/00; G01N \$5/48, \$5/50; G06T 1/00  US CL :545/418, 961; 702/18, 20; 707/100, 102, 104  According to International Patent Classification (IPC) or to both national classification and IPC				
	LDS SEARCHED			
Minimum o	documentation searched (classification system follow	ved by classification syn	nbols)	
U.S. :	345/418, 961; 702/19, 20; 707/100, 102, 104			
Documenta searched	tion searched other than minimum documentation	to the extent that such	documents are	included in the fields
	data base consulted during the international search e Extra Sheet.	(name of data base and,	where practicab	e, search terms used)
C. DOC	UMENTS CONSIDERED TO BE RELEVANT			
Category*	Citation of document, with indication, where a	ppropriate, of the relev	ant passages	Relevant to claim No.
<b>Y</b>	US 5,874,256 A (BERTINA ET AL) see in particular abstract and claims.	23 February 1999	(23-02-99),	1-21,30-33, 35,43-51,53-58,69-78,83-84,86,94-102,104-109,120-129,134-135,137,145-153,155-160,171-183
X Furth	er documents are listed in the continuation of Box	C. See patent	family annex.	
- 6p-	cial categories of cited documents:	"I" later document y	phlished after the inte	mational filing date or priority
"A" door	ument defining the general state of the art which is not considered	date and not in	conflict with the appl theory underlying the	ication but cited to understand
	e of particular relevance tiar document published on or after the international filing date			claimed invention cannot be
"L" document which may throw doubts on priority claim(s) or which is			l or cannot be consider sent is taken alone	ed to involve an inventive step
cited to establish the publication date of another citation or other special reason (as specified)				claimed invention cannot be
"O" - door	nment referring to an oral disclosure, use, exhibition or other	with one or me	mercol done redio esc	when the document is combined onts, such combination being
"P" door	document published prior to the international filing date but later "A" document member of the same patent family than the priority date claimed			family
Date of the	Date of the actual completion of the international search  Date of mailing of the international search report			
14 NOVE	MBER 2000		23 F	EB 2001
Name and mailing address of the ISA/US  Commissioner of Patents and Trademarks  Box PCT  Authorized officer  Authorized officer  Authorized Officer  Authorized Officer  Authorized Officer				
Box PCT	er of Patents and Trademarks D.C. 20231	MARIANNE P. A	ACCUSED LLEN	ce for
Facsimile No	o. (703) 30 <i>5</i> -3230	Telephone No. (70	3) 508-0196	